SLC29A1 and familial pancreatic carcinoma: In conclusion, we have shown that in vitro chemosensitivity testing using the ATP-TCA test or expression analysis of the drug transporter hENT1 is feasible and may predict the response to gemcitabine chemotherapy in pancreatic cancer.